Cygnus GlucoWatch Launch Contingent On AutoSensor Facility Clearance
This article was originally published in The Gray Sheet
Full-scale U.S. launch of Cygnus' GlucoWatch Biographer non-invasive glucose monitoring system will await FDA approval of a primary manufacturing site for the AutoSensor component, the firm says.
You may also be interested in...
An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.